Steven Cohen’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Steven Cohen’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-388,613	Closed	-$9.19M	–	1374
2019 Q3	$9.19M	Sell	388,613 -195,200	-33%	-$5.78M	0.06%	372
2019 Q2	$17.6M	Buy	583,813 +378,813	+185%	+$8.68M	0.09%	275
2019 Q1	$4.59M	Buy	205,000 +145,400	+244%	+$3.13M	0.02%	571
2018 Q4	$1.08M	Sell	59,600 -18,599	-24%	-$292K	0.01%	799
2018 Q3	$1.42M	Buy	+78,199	New	+$927K	0.01%	814
2018 Q1	–	Sell	-100,000	Closed	-$850K	–	1210
2017 Q4	$850K	Buy	+100,000	New	+$1.23M	﹤0.01%	815

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steven Cohen's RARX Position: Q4 2019 in Review

Steven Cohen sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 388,613 shares — an estimated $9.19M sold.

Steven Cohen first reported a position in RARX in Q4 2017 and held it in 6 quarters. The position peaked at $17.6M in Q2 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

Steven Cohen reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Steven Cohen sold 388,613 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $9.19M.
Steven Cohen first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 6 quarters.
Steven Cohen's Ra Pharmaceuticals, Inc. Common Stock position peaked at $17.6M in Q2 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Point72 Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.